Summit Therapeutics Receives $200M Investment and Expands Ivonescimab License Territories
Key Highlights $200M investment from an institutional investor at $9.00 per share. Expansion of ivonescimab license territories to Latin America,…
Browsing Tag
Summit Therapeutics Inc.
1 post